Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEBRA Trial
NCT06561347Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in Waldenström macroglobulinemia (WM), sponsored by Massachusetts General Hospital. Primary endpoint: Very Good Partial Response or Better Response Rate. Started Dec 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06561347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561347.